Skip to main content

Table 1 Demographics and clinical characteristics of the study participants

From: Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort

  Total OC aMCI ADD SVCI CAA YC
N 580 149 212 134 58 12 15
Age (years) 69.8 ± 11.0 69.6 ± 7.7 70.0 ± 8.3 70.2 ± 11.0 77.4 ± 8.5*,†,$ 76.8 ± 6.9 32.5 ± 3.9*,†,$
Female sex 362 (62.4) 98 (65.8) 119 (56.1) 90 (67.7) 44 (74.6) 6 (50.0) 6 (40.0)*,$,^
APOE4 carrier 214 (36.9) 38 (25.5) 85 (40.1)* 75 (56.4)*,† 12 (20.3)†,$ 1 (8.3)†,$ 3 (20.0)$
PET positivitya 280/578b (48.4) 17 (11.4) 119 (56.1)* 113/133 (85.0)*,† 22 (37.9)*,†,$ 9/11 (81.8)*,^ 0 (0.0)†,$,^,#
MMSE 24 ± 5.4 27.8 ± 2.5 22.5 ± 3.3* 18.5 ± 5.3*,† 22 ± 5.4*,†,$ 21 ± 7.3*,$ N/A
Plasma Aβ42 56.9 ± 16.2 (n = 577) 60 ± 14.4 56.1 ± 16.3 51.7 ± 15.5* 64.8 ± 18.2†,$ 55.7 ± 20.3 52.2±5^
Plasma Aβ40 217 ± 58.2 (n = 572) 215.8 ± 52.5 216 ± 55 210.8 ± 60.3 241.7 ± 68.1*,†,$ 237.1 ± 86.4 184.4 ± 15.6^
Plasma Aβ42/Aβ40 0.27 ± 0.06 (n = 572) 0.28 ± 0.05 0.27 ± 0.05* 0.26 ± 0.08* 0.28 ± 0.07 0.24 ± 0.03 0.28 ± 0.03
  1. Values are presented as mean ± standard deviation or number (%) as appropriately
  2. ADD Alzheimer’s disease dementia; aMCI amnestic mild cognitive impairment; OC old controls; SVCI subcortical vascular cognitive impairment; CAA cerebral amyloid angiopathy; YC young controls
  3. aPET positivity is based on the centiloid unit
  4. bTwo patients were excluded due to image processing errors
  5. *p < 0.05 compared to OC
  6. p < 0.05 compared to aMCI
  7. $p < 0.05 compared to ADD
  8. ^p < 0.05 compared to SVCI
  9. #p < 0.05 compared to CAA